Flputnam Investment Management Co. Raises Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Flputnam Investment Management Co. significantly increased its stake in Gilead Sciences, purchasing an additional 24,599 shares, bringing its total holdings to 30,371 shares valued at approximately $3.4 million.
• Gilead Sciences reported a quarterly EPS of $2.01, exceeding analyst expectations and reflecting a year-over-year revenue increase of 1.4% to $7.08 billion.
• The company has announced a quarterly dividend of $0.79 per share, which will be paid to shareholders on September 29th, resulting in an annual yield of 2.8%.

Flputnam Investment Management Co. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 426.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,371 shares of the biopharmaceutical company's stock after acquiring an additional 24,599 shares during the period. Flputnam Investment Management Co.'s holdings in Gilead Sciences were worth $3,403,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter valued at about $25,000. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter valued at about $29,000. Colonial Trust Advisors boosted its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer directly owned 595,725 shares of the company's stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer directly owned 160,110 shares of the company's stock, valued at $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock valued at $9,371,330. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 2.0%

GILD stock traded up $2.28 during mid-day trading on Friday, reaching $115.05. 6,859,612 shares of the stock traded hands, compared to its average volume of 8,095,162. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $78.26 and a one year high of $121.83. The stock has a market capitalization of $142.76 billion, a PE ratio of 22.92, a PEG ratio of 0.77 and a beta of 0.36. The business has a 50-day moving average price of $113.50 and a two-hundred day moving average price of $109.82.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.